{"id":"toripalimab-mimetic-placebo","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, Toripalimab mimetic allows T cells to recognize and attack cancer cells more effectively. This mechanism is particularly useful in treating various types of cancer, including non-small cell lung cancer and nasopharyngeal carcinoma.","oneSentence":"Toripalimab mimetic is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:27.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Nasopharyngeal carcinoma"}]},"trialDetails":[{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin/Carboplatin","Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel"],"phase":"phase_3","status":"active","brandName":"Toripalimab mimetic (placebo)","genericName":"Toripalimab mimetic (placebo)","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab mimetic is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Nasopharyngeal carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}